Is there an association between the level of high-sensitivity C-reactive protein and idiopathic parkinson's disease? a comparison of parkinson's disease patients, disease controls and healthy individuals

European Neurology

Volumn 62, Issue 2, 2009, Pages 99-104

  Song, In Uk ^a   Kim, Joong Seok ^a   Chung, Sung Woo ^a   Lee, Kwang Soo ^a,b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

High sensitivity C reactive protein; Idiopathic Parkinson's disease; Neuroinflammation

Indexed keywords

C REACTIVE PROTEIN;

ACUTE DISEASE; AGED; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PATIENT CODING; POST HOC ANALYSIS; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

AGED; ANALYSIS OF VARIANCE; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; FEMALE; HUMANS; LOGISTIC MODELS; MALE; ODDS RATIO; PARKINSON DISEASE; STROKE;

EID: 66749129095     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000222780     Document Type: Article

References (38)

1. Pepys MB, Hirschfield GM: C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805 -1812.
2. Palasik W, Fiszer U, Lechowicz W, Czartoryska B, Krzesiewicz M, Lugowska A: Assessment of relations between clinical outcome of ischemic stroke and activity of inflammatory processes in the acute phase based on examination of selected parameters. Eur Neurol 2005; 53:188-193.
3. Pepys MB, Baltz ML: Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 1983; 34: 141-212 .
4. Nakase T, Yamazaki T, Ogura N, Suzuki A, Nagata K: The impact of inflammation on the pathogenesis and prognosis of ischemic stroke. J Neurol Sci 2008; 271:104-109.
5. Libby P: Inflammation in atherosclerosis. Nature 2002; 420: 868-874 .
6. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F, Centers for Disease Control and Prevention, American Heart Association: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 10 7: 499-511.
7. Rothwell PM, Howard SC, Power DA, Gutnikov SA, Algra A, van Gijn J, Clark TG, Murphy MF, Warlow CP: Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke 2004; 35:2300-2305.
8. Winbeck K, Poppert H, Etgen T, Conrad B, Sander D: Prognostic relevance of early serial C-reactive protein measurements after f irst ischemic stroke. Stroke 2002; 33: 2459- 2464.
9. Rosenson RS, Koenig W: High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease. Curr Opin Cardiol 2002; 17:325-331.
10. Maries E, Dass B, Collier TJ, Kordower JH, Steece-Collier K: The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci 2003; 4: 727-738 .
11. Dauer W, Przedborski S: Parkinson's disease: mechanisms and models. Neuron 2003; 39: 889-909.
12. Wersinger C, Sidhu A: An inflammatory pathomechanism for Parkinson's disease? Curr Med Chem 2006; 13:591-602.
13. McGeer PL, Itagaki S, Boyes BE, McGeer EG: Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988; 38:1285-1291.
14. McGeer PL, McGeer EG: Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 2004; 10(suppl 1): S3-S7.
15. Chen H, Zhang SM, Hernán MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE, Ascherio A: Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003; 60:1059-1064.
16. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A: Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 2005; 58:963-967.
17. Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184 .
18. Hoehn MM, Yahr MD: Parkinsonism: onset, progression and mortality. Neurology 1967; 17:427-442.
19. Foulkes MA, Wolf PA, Price TP, Mohr JP, Hier DB: The stroke data bank: design, methods, and baseline characteristics. Stroke 1988; 19:547-554.
20. Di Napoli M, Papa F, Bocola V: C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke 2001; 32:917-924.
21. Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM: A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 2005; 128:2665-2674.
22. Depino AM, Earl C, Kaczmarczyk E, Ferrari C, Besedovsky H, del Rey A, Pitossi FJ, Oertel WH: Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur J Neurosci 2003; 18:2731-2742.
23. Nagatsu T, Sawada M: I nf la m mator y process in Parkinson's disease: role for cytokines. Curr Pharm Des 2005; 11:999-1016.
24. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T: Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 2005; 57: 16 8 -17 5 .
25. Kreutzberg GW: Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996; 19:312-318.
26. Kuo HK, Yen CJ, Chang CH, Kuo CK, Chen JH, Sorond F: Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol 2005; 4:371-380.
27. Davis GK, Baboolal NS, Seales D, Ramchandani J, McKell S, McRae A: Potential biomarkers for dementia in Trinidad and Tobago. Neurosci Lett 2007; 424:27-30.
28. Hüll M, Strauss S, Berger M, Volk B, Bauer J: Inflammatory mechanisms in Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 1996; 246:124-128.
29. Napoli MD, Papa F: Association between blood pressure and C-reactive protein levels in acute ischemic stroke. Hypertension 2003; 42:1117-1123.
30. McGeer PL, McGeer EG: Inflammation and the degenerative disease of aging. Ann NY Acad Sci 2004; 1035:104-116.
31. Wilms H, Zecca L, Rosenstiel P, Sievers J, Deuschl G, Lucius R: Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications. Curr Pharm Des 2007; 13:1925-1928.
32. Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A: Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol 2008; 16 7: 90-95.
33. Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G: Nonsteroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol 2007; 205: 295-312.
34. Olanow CW: The pathogenesis of cell death in Parkinson's disease - 2007. Mov Disord 2007; 22(suppl 17):S335-S342.
35. McGeer PL, McGeer EG: The role of anti-inflammatory agents in Parkinson's disease. CNS Drugs 2007; 21: 789-797.
36. Ton TG, Heckbert SR, Longstreth WT Jr, Rossing MA, Kukull WA, Franklin GM, Swanson PD, Smith-Weller T, Checkoway H: Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov Disord 2006; 21:964-969.
37. Kim SR, Lee TY, Kim MS, Lee MC, Chung SJ: Use of complementary and alternative medicine by Korean patients with Parkinson's disease. Clin Neurol Neurosurg 2009; 111: 156 -160.
38. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340:448-454.